The results revealed that through various mechanisms, genes such as Excision Repair Cross-Complementation group 1 (ERCC1), ERCC2/xeroderma pigmentosum complementation group D (XPD), xeroderma pigmentosum complementation group C (XPC), and xeroderma pigmentosum complementation group A (XPA) have been associated with patient response to Pt-based chemotherapy. This evidence concerns the gene ERCC2 and Xeroderma pigmentosum complementation group C.